Home > Resources > Whitepapers > WHAT HEALTHCARE ORGANIZATIONS SHOULD KNOW ABOUT THE GDPR

WHAT HEALTHCARE ORGANIZATIONS SHOULD KNOW ABOUT THE GDPR

June 19, 2018

THE HEALTHCARE INDUSTRY IS FACING MULTIPLE CHALLENGES WHEN IT COMES TO PROTECTING SENSITIVE DATA. HERE’S AN OVERVIEW OF HOW THE RECENT EU GENERAL DATA PROTECTION REGULATIONS (GDPR) WILL AFFECT HEALTHCARE ORGANIZATIONS

Spotlight

MTHFR Genetics UK (Lab)

We are all about empowering you, in knowledge about your body's biochemistry. Right down to the level of your genetics, and encouraging you to take a proactive approach to improving your health. This can be accomplished by applying lifestyle changes and reducing exposure to environmental factors, that may contribute to, or cause your genetic mutations to start expressing, causing a decline in your health as a result.

OTHER WHITEPAPERS

A New Generation of Cancer Immunotherapies

whitePaper | June 9, 2022

Despite recent progress in fighting cancer the sad reality is that it remains a leading cause of morbidity and mortality. Some of the most promising new treatments have emerged from the convergence of the oncology and immunology fields.

Internal Co-ordination Group for Biotechnology

whitePaper | October 19, 2022

The Organisation for Economic Co-operation and Development and its member countries have been addressing issues related to biotechnology since 1982.

Accelerating Global Access to Gene Therapies: Case Studies from Lowand Middle-Income Countries

whitePaper | October 18, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

Multi-Specific Monoclonal Antibodies

whitePaper | February 22, 2023

The reason for the rapid expansion and development of the therapeutic antibody sector is the capacity of monoclonal antibodies to precisely bind a target antigen and neutralise or promote its activity. The efficacy and safety.

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).